Literature DB >> 24029565

[Preoperative evaluation of vascular involvement and general resectability of pancreatic carcinoma by using 64-slice spiral computed tomographical angiography].

Yun Zhang1, Zhi-jie Jian, Ting-ting Zhao, Yu-xin Fan, Shao-hui Ma, Lin Wang, Liang Yu, Chang Liu.   

Abstract

OBJECTIVE: To assess for preoperative evaluation of 64-slice spiral computed tomographical angiography (64-SCTA) to predict vascular involvement and general resectability of pancreatic malignant tumors.
METHODS: The material of 64-SCTA in 34 cases were retrospectively analyzed. Preoperative imaging findings were correlated with intraoperative and histopathologic results.
RESULTS: For the arterial tumor invasion based on 64-SCTA findings, 1 grade was in 8 cases; 2 grade, 6 cases; 3 grade, 8 cases; 4 grade, 10 cases;5 grade, 2 cases.Regarding respectability, the sensitivity, specificity, accuracy, positive predictive value (PPV), negative predictive value (NPV) were 92.9%, 95.0%,94.1%, 92.9%, 95.0%. Kappa value was 0.879 (P < 0.01). Receiver operator characteristic (ROC) analysis revealed an area under the curve (AUC) of 0.943 (P < 0.01). For the venous tumor infiltration, 1 grade was in 0 case; 2 grade, 6 cases; 3 grade, 6 cases; 4 grade, 13 cases; 5 grade, 9 cases. Regarding respectability, these values for those tumors with vein invasion were 78.6%, 95.0%, 88.2%, 91.7%, 86.4%. Kappa value was 0.752 (P < 0.01). ROC analysis showed an AUC of 0.927 (P < 0.01).
CONCLUSION: 64-SCTA can provide reliable information for vascular involvement and general resectability of pancreatic malignant tumors. 64-SCTA has high value in clinical application.

Entities:  

Mesh:

Year:  2013        PMID: 24029565

Source DB:  PubMed          Journal:  Zhonghua Yi Xue Za Zhi        ISSN: 0376-2491


  1 in total

1.  Pancreatic cancer with portal vein invasion diagnosed by endoscopic ultrasound.

Authors:  Augusto P C Carbonari; Juliana Bonfim; Rogerio Colaiacovo; Lucio G B Rossini
Journal:  Endosc Ultrasound       Date:  2015 Apr-Jun       Impact factor: 5.628

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.